It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Compare yields across Ex Us dividend ETFs to see which funds currently offer the highest income potential and sustainable payouts.
27,628 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As 2026 unfolds, REITs offer liquidity and steady income in a rate-sensitive environment. This report highlights the ...
VGIT remains a stable Treasury income option as yields swing with policy signals. This report analyzes how duration r...
Wake up to a clear, actionable investing briefing. This Thursday reads roundup distills ten essential market themes i...
Nokomis Capital quietly builds a new position in Apple Hospitality REIT, underscoring a rising appetite for hospitali...
Market turbulence can unveil compelling buying opportunities. Learn why market crash: financial stocks deserve a plac...
A beginner-friendly look at how big investment moves in real estate investment trusts signal risk and income opportun...
A closer look at Janus Henderson's CLO ETFs shows a safety-first anchor in JAAA and a bolder, higher-yield challenger...
A timely analysis of pff’s billion preferred stock exposure reveals how call provisions and a bank-heavy portfolio co...
A healthcare-focused dividend stock surged last year, outpacing the Nasdaq and delivering solid income. Analysts see ...
DGRO targets companies with five straight years of dividend growth and a cap on payout ratios, aiming for a rising in...
XLRE has surged about 11% year-to-date, but analysts warn that rising yields could pressure capital gains while AFFO-...